Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Income from Continuing Operations (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Income from Continuing Operations for 11 consecutive years, with 18932000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 33.33% to 18932000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 91744000.0 through Dec 2025, up 22.23% year-over-year, with the annual reading at 91744000.0 for FY2025, 21.82% up from the prior year.
  • Income from Continuing Operations hit 18932000.0 in Q4 2025 for Seres Therapeutics, up from 21859000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 68253000.0 in Q3 2021 to a low of 71484000.0 in Q1 2023.
  • Historically, Income from Continuing Operations has averaged 27880300.0 across 5 years, with a median of 30963000.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: surged 322.87% in 2021 and later plummeted 1495.49% in 2023.
  • Year by year, Income from Continuing Operations stood at 49685000.0 in 2021, then soared by 95.58% to 2197000.0 in 2022, then tumbled by 1495.49% to 35053000.0 in 2023, then increased by 18.99% to 28398000.0 in 2024, then skyrocketed by 33.33% to 18932000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for MCRB at 18932000.0 in Q4 2025, 21859000.0 in Q3 2025, and 24335000.0 in Q2 2025.